[BEIJING, Aug. 27, 2014 /PRNewswire/ -- Sinovac Biotech Ltd. (SVA), a leading provider of biopharmaceutical products in China, today announced the results of the Company's 2014 Annual General Meeting of Shareholders held on Wednesday, August 27, 2014 in Beijing, PRC. The required quorum, a majority of the common shares outstanding, was voted by proxy. The Company's shareholders approved the following] []
[BEIJING, Aug. 27, 2014 /PRNewswire/ -- Sinovac Biotech Ltd. (SVA), a leading provider of biopharmaceutical products in China, today announced the results of the Company's 2014 Annual General Meeting of Shareholders held on Wednesday, August 27, 2014 in Beijing, PRC. The required quorum, a majority of the common shares outstanding, was voted by proxy. The Company's shareholders approved the following] []
[Sinovac Receives Tender to Supply Inactivated Hepatitis A Vaccine Healive in Beijing Under Expanded Immunization Program BEIJING, July 21, 2014 /PRNewswire/ -- Sinovac Biotech Ltd. (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, announced today that it has been selected by the Beijing Health Bureau as the sole supplier of inactivated hepatitis A vaccine in pre-filled syringe dosage] [Sinovac Receives Beijing CDC Tender to Supply Seasonal Flu Vaccine Anflu BEIJING, July 23, 2014 /PRNewswire/ -- Sinovac Biotech Ltd. (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, announced today that it has been selected by the Beijing Centers for Disease Control and Prevention ("Beijing CDC") to be a supplier of the seasonal influenza vaccine to the citizens] [Sinovac to Host Conference Call to Report Second Quarter 2014 Unaudited Financial Results BEIJING, July 25, 2014 -- Sinovac Biotech Ltd. (Nasdaq: SVA), a leading provider of biopharmaceutical products in China, today announced that it will release its unaudited financial results for the second quarter ended June 30, 2014, after market close on Thursday, August 14, 2014 EDT. The Company] []
[-- Conference call scheduled for Friday, August 15, 2014 at 8:00 AM ET -- BEIJING, Aug.14, 2014 /PRNewswire/ -- Sinovac Biotech Ltd. (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, announced today its unaudited second quarter and half year financial results for the period ended June 30, 2014. Second Quarter 2014 Financial Highlights compared to the second quarter] []
[-- Conference call scheduled for Friday, August 15, 2014 at 8:00 AM ET -- BEIJING, Aug.14, 2014 /PRNewswire/ -- Sinovac Biotech Ltd. (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, announced today its unaudited second quarter and half year financial results for the period ended June 30, 2014. Second Quarter 2014 Financial Highlights compared to the second quarter] []
[Sinovac Receives Tender to Supply Inactivated Hepatitis A Vaccine Healive in Beijing Under Expanded Immunization Program BEIJING, July 21, 2014 /PRNewswire/ -- Sinovac Biotech Ltd. (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, announced today that it has been selected by the Beijing Health Bureau as the sole supplier of inactivated hepatitis A vaccine in pre-filled syringe dosage] [Sinovac Receives Beijing CDC Tender to Supply Seasonal Flu Vaccine Anflu BEIJING, July 23, 2014 /PRNewswire/ -- Sinovac Biotech Ltd. (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, announced today that it has been selected by the Beijing Centers for Disease Control and Prevention ("Beijing CDC") to be a supplier of the seasonal influenza vaccine to the citizens] [Sinovac to Host Conference Call to Report Second Quarter 2014 Unaudited Financial Results BEIJING, July 25, 2014 -- Sinovac Biotech Ltd. (Nasdaq: SVA), a leading provider of biopharmaceutical products in China, today announced that it will release its unaudited financial results for the second quarter ended June 30, 2014, after market close on Thursday, August 14, 2014 EDT. The Company] []
[Sinovac Schedules 2014 Annual Meeting of Shareholders BEIJING, July 14, 2014 -- Sinovac Biotech Ltd. (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, announced today that it will hold its 2014 Annual Meeting of Shareholders on Wednesday, August 27, 2014 at 9:00 a.m. Beijing Time. The meeting will be held at No. 39 Shangdi Xi Road, Haidian District,] [July 15, 2014 Dear Shareholder: You are cordially invited to attend the 2014 annual meeting of shareholders of Sinovac Biotech Ltd. to be held on August 27, 2014, at 9:00 A.M. Beijing time, at No. 39 Shangdi Xi Road, Haidian District, Beijing 100085, People’s Republic of China. At this year’s annual meeting, you will be asked to: · approve the] []
[Sinovac Schedules 2014 Annual Meeting of Shareholders BEIJING, July 14, 2014 -- Sinovac Biotech Ltd. (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, announced today that it will hold its 2014 Annual Meeting of Shareholders on Wednesday, August 27, 2014 at 9:00 a.m. Beijing Time. The meeting will be held at No. 39 Shangdi Xi Road, Haidian District,] [July 15, 2014 Dear Shareholder: You are cordially invited to attend the 2014 annual meeting of shareholders of Sinovac Biotech Ltd. to be held on August 27, 2014, at 9:00 A.M. Beijing time, at No. 39 Shangdi Xi Road, Haidian District, Beijing 100085, People’s Republic of China. At this year’s annual meeting, you will be asked to: · approve the] []
[Sinovac Announces Favorable Reduction in Value Added Tax Rate BEIJING, June 25, 2014 /PRNewswire/ -- Sinovac Biotech Ltd. (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, today announced that the value added tax (or "VAT") rate applied to the sales of Sinovac's vaccine products will be reduced to 3% from the current rate of 6%, according to a] []
[Sinovac Announces Favorable Reduction in Value Added Tax Rate BEIJING, June 25, 2014 /PRNewswire/ -- Sinovac Biotech Ltd. (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, today announced that the value added tax (or "VAT") rate applied to the sales of Sinovac's vaccine products will be reduced to 3% from the current rate of 6%, according to a] []
